Degrading Immune Checkpoints and Coordinating Oncogenic Signaling: Emerging Strategies in Cancer Therapy

Targeted protein degradation and rational combination therapy redefine Cancer treatment by addressing both immune suppression and tumor-intrinsic signaling. Bifunctional degraders eliminate key regulatory kinases, while dual-pathway inhibition suppresses compensatory survival mechanisms. These complementary approaches illustrate a shift toward coordinated therapeutic control, enabling more durable antitumor responses through simultaneous modulation of immune activation and oncogenic pathways.